Menu

Organoid Biobank

From the tissue of numerous colon cancer patients, researchers build 3-D cultures of tumors.

May 11, 2015
Kerry Grens

VAN DE WETERING ET AL./CELL 2015To more faithfully recapitulate cancers in the lab, researchers have built upon existing methods for creating three-dimensional intestines in a dish to grow these so-called organoids out of tumor samples. The scientists used tissue from 20 colorectal cancer patients to create 22 tumor-derived organoids and 19 organoids from the patients’ normal intestinal tissue.

“This is the first time that a collection of cancer organoids, or a living biobank, has been derived from patient tumors,” study coauthor Mathew Garnett, a geneticist at the Wellcome Trust Sanger Institute, said in a press release. “We believe that these organoids are an important new tool in the arsenal of cancer biologists and may ultimately improve our ability to develop more effective cancer treatments.”

Currently, cells lines and xenotransplantation of tumors into mice are the best methods for studying cancers in the laboratory. But cell lines offer only a short-term glimpse of the cancer, and mouse models can be resource-intensive, the authors wrote in their report, published in Cell last week (May 7).

Garnett and his colleagues analyzed genetic mutations of the cancerous organoids, finding them similar to the original tumors. “They capture most if not all of the most important mutations,” Eduard Batlle at the Institute for Research in Biomedicine in Barcelona, Spain, who was not part of the study told Science News. Then the team used the organoids to screen 83 drugs, finding the tumor cultures responded as would be expected based on their genetic profiles.

“Here, we demonstrate that the organoid culture platform can be exploited for genomic and functional studies at the level of the individual patient at a scale that cannot be achieved by existing approaches,” the authors wrote.

According to Science News, two clinical trials are already taking advantage of tumor-derived organoids. One is examining how well organoids can predict a patient’s response to a drug, and the other will look at potential treatments for patients with a cancer that has spread in the body.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.